SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · BioNTech announced the appointment of Guido Oelkers, Ph.D., as the new…

BioNTech SE · PRESS-RELEASE filed Aug 3, 2026 at 05:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Aug 3, 2026 at 05:00 ET

BioNTech announced the appointment of Guido Oelkers, Ph.D., as the new CEO, effective by February 1, 2027, succeeding co-founder Prof. Ugur Sahin. Oelkers joins from Sobi, where he more than quadrupled revenues over nine years. This leadership transition is a routine succession event for a company in a pivotal phase, with no immediate financial impact or change to the pipeline strategy.

  • Guido Oelkers appointed as CEO, effective by February 1, 2027
  • Oelkers succeeds Prof. Ugur Sahin, who will support the transition
  • Oelkers previously served as CEO of Sobi, where he more than quadrupled revenues from 2017 to 2026
  • Prof. Özlem Türeci will transition to lead a new independent company with Prof. Sahin

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access